Side-by-side comparison

LLY vs BSX — Side-by-side comparison

BSX screens cheaper on EV/FCF, LLY has the higher ROIC, LLY has grown revenue faster over five years, and BSX has the cleaner balance sheet by net debt / EBITDA.

LLY

Eli Lilly & Co.

Price

$1065.00

Market cap

$737.7B

Day %

N/A

BSX

Boston Scientific

Price

$57.78

Market cap

$154.2B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


LLY Target	Eli Lilly & Co.	$737.7B	46.4x	43.4x	77.8%	21.6%	25.8%	N/A	N/A	N/A
BSX	Boston Scientific	$154.2B	29.8x	41.6x	11.9%	15.2%	18.2%	69.0%	-0.4x	N/A

LLY implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

43.4x

FCF yield

2.3%

5Y rev CAGR

21.6%

BSX implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

41.6x

FCF yield

2.4%

5Y rev CAGR

15.2%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for LLY.

Grade C

/ 100

Quality Scorecard

Build-time composite score for BSX.

Grade C

/ 100